CN101198623B - 用于调控和检测wisp活性的方法和组合物 - Google Patents

用于调控和检测wisp活性的方法和组合物 Download PDF

Info

Publication number
CN101198623B
CN101198623B CN2006800215473A CN200680021547A CN101198623B CN 101198623 B CN101198623 B CN 101198623B CN 2006800215473 A CN2006800215473 A CN 2006800215473A CN 200680021547 A CN200680021547 A CN 200680021547A CN 101198623 B CN101198623 B CN 101198623B
Authority
CN
China
Prior art keywords
wisp
cell
antibody
polypeptide
nrk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2006800215473A
Other languages
English (en)
Chinese (zh)
Other versions
CN101198623A (zh
Inventor
卢克·德斯诺耶斯
埃伦·菲尔瓦罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101198623A publication Critical patent/CN101198623A/zh
Application granted granted Critical
Publication of CN101198623B publication Critical patent/CN101198623B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2006800215473A 2005-04-14 2006-04-13 用于调控和检测wisp活性的方法和组合物 Expired - Lifetime CN101198623B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/105,876 2005-04-14
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (2)

Publication Number Publication Date
CN101198623A CN101198623A (zh) 2008-06-11
CN101198623B true CN101198623B (zh) 2013-06-12

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800215473A Expired - Lifetime CN101198623B (zh) 2005-04-14 2006-04-13 用于调控和检测wisp活性的方法和组合物

Country Status (16)

Country Link
US (2) US7455834B2 (https=)
EP (1) EP1869086B1 (https=)
JP (1) JP4979684B2 (https=)
KR (1) KR101320261B1 (https=)
CN (1) CN101198623B (https=)
AU (1) AU2006236649B2 (https=)
BR (1) BRPI0612184A8 (https=)
CA (1) CA2604933C (https=)
ES (1) ES2388993T3 (https=)
IL (1) IL186095A (https=)
MX (1) MX2007012798A (https=)
NO (1) NO20075825L (https=)
NZ (1) NZ561709A (https=)
RU (1) RU2412201C2 (https=)
WO (1) WO2006113402A1 (https=)
ZA (1) ZA200708738B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
KR102148303B1 (ko) 2012-02-11 2020-08-26 제넨테크, 인크. R-스폰딘 전위 및 그의 사용 방법
MX2015013658A (es) * 2013-03-27 2016-02-18 Ge Healthcare As Metodo y reactivo para preparar una composicion diagnostica.
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
EP3795170B1 (en) * 2018-05-17 2024-03-20 Olives Biotherapeutics Inc. Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE363489T1 (de) 1999-03-08 2007-06-15 Genentech Inc In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
WO2005025603A2 (en) 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAXENA NEELA ET AL.differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines.《MOLECULAR AND CELLULAR BIOCHMISTRY》.2001,第228卷(第1-2期),99-104. *

Also Published As

Publication number Publication date
JP4979684B2 (ja) 2012-07-18
WO2006113402A1 (en) 2006-10-26
US7455834B2 (en) 2008-11-25
IL186095A (en) 2012-10-31
US20060147453A1 (en) 2006-07-06
HK1112470A1 (en) 2008-09-05
JP2008537958A (ja) 2008-10-02
BRPI0612184A8 (pt) 2017-12-26
AU2006236649B2 (en) 2012-03-29
MX2007012798A (es) 2007-11-20
CA2604933C (en) 2014-07-08
RU2007142005A (ru) 2009-05-20
EP1869086A1 (en) 2007-12-26
NZ561709A (en) 2009-12-24
IL186095A0 (en) 2008-01-20
AU2006236649A2 (en) 2008-07-24
ZA200708738B (en) 2009-01-28
AU2006236649A1 (en) 2006-10-26
BRPI0612184A2 (pt) 2011-12-20
CA2604933A1 (en) 2006-10-26
EP1869086B1 (en) 2012-07-18
CN101198623A (zh) 2008-06-11
US7732567B2 (en) 2010-06-08
RU2412201C2 (ru) 2011-02-20
ES2388993T3 (es) 2012-10-22
KR20080003344A (ko) 2008-01-07
US20090148448A1 (en) 2009-06-11
KR101320261B1 (ko) 2013-10-22
NO20075825L (no) 2008-01-11

Similar Documents

Publication Publication Date Title
CN101563105B (zh) 用于抑制smad4-缺陷癌症的组合物和方法
Vitale et al. Animal models of medullary thyroid cancer: state of the art and view to the future
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
US7456262B2 (en) Methods and composition for modulating and detecting wisp activity
CN101175769A (zh) 用于调控血管完整性的方法和组合物
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
AU2004272066B2 (en) Methods of using WISP antagonists
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity
US20230133201A1 (en) Methods and materials for disseminating a protein throughout the central nervous system
Wong Genetic and mechanistic determinants of prostate cancer progression and metastasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20130612